Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and/or soles of the feet, which can progress to blistering. Hand-foot skin reaction (HFSR) refers to symptoms affecting the hands and/or feet associated with multikinase inhibitors (TKIs). HFS and HFSR are painful complications that can lead to compromised daily activities, sleep-wake disturbance and impaired mobility, eventually decreasing Quality of Life (QoL). Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and/or near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. The aim of this study is to evaluate the effectiveness of PBMT in the management of HFS and HFSR.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Skin reaction evaluation - CTCAE
Timeframe: Baseline
Skin reaction evaluation - CTCAE
Timeframe: Session 3 of PBMT
Skin reaction evaluation - CTCAE
Timeframe: Session 6 of PBMT
Skin reaction evaluation - CTCAE
Timeframe: Final PBM session (session 9)
Skin reaction evaluation - CTCAE
Timeframe: 2 weeks post-PBMT
Skin reaction evaluation - WHO
Timeframe: Baseline
Skin reaction evaluation - WHO
Timeframe: Session 3 of PBMT
Skin reaction evaluation - WHO
Timeframe: Session 6 of PBMT
Skin reaction evaluation - WHO
Timeframe: Final PBM session (session 9)
Skin reaction evaluation - WHO
Timeframe: 2 weeks post-PBMT
Clinical photograph
Timeframe: Baseline
Clinical photograph
Timeframe: Session 3 of PBMT
Clinical photograph
Timeframe: Session 6 of PBMT
Clinical photograph
Timeframe: Final PBM session (session 9)
Clinical photograph
Timeframe: 2 weeks post-PBMT